Priority List of Adverse Events of Special Interest: COVID-19
June 10, 2020
News / Relevant for COVID-19
The Coalition for Epidemic Preparedness Innovations (CEPI) has contracted with the Brighton Collaboration, through the Task Force for Global Health (TFGH), to harmonize the safety assessment of CEPI-funded vaccines via its Safety Platform for Emergency vACcines (SPEAC) Project. As part of its landscape analysis of COVID-19, this document describes the methods and results SPEAC used to arrive at the list of adverse events of special interest (AESI).(brightoncollaboration.us/priority-list-aesi-covid/)
Click here to download the Priority List of Adverse Events of Special Interest: COVID-19 document.
@Pope Innocent lll In Spain, health care workers are reporting a large volume of adverse effects, so the government asked them not to report all adverse effects and sent them a list of which ones should be reported, and the link to this document was also included in that statement.
GOB. PIDE A LOS SANITARIOS: QUE NO COMUNIQUEN TODOS LOS EFECTOS ADVERSOS PORQUE SON MUCHOS, SOLO DEBEN INFO. LOS SIGUIENTES:
@Pope Innocent lll Given the large volume of known adverse effects reported for Covidien-19 vaccines through the Yellow Card Program (www.targetagroga.cat), and to facilitate the identification of new safety problems with Covidien-19 vaccines , we ask that you only notify us of the following adverse effects from now on: Unknown and / or serious, especially if they motivate a hospital admission, endanger life or have a fatal outcome.
Adverse events of special interest (1): anaphylaxis, arrhythmia, heart failure, stress cardiomyopathy, coronary artery disease, myocarditis, sudden death or death of any cause, Guillain-Barré syndrome, acute disseminated encephalomyelitis, narcolepsy, generalized seizure, meningoencephalitis , transverse myelitis, Bell's palsy, cutaneous vasculitis, erythema multiforme, microangiopathy, coagulation disorders (thromboembolism and bleeding), idiopathic thrombocytopenia, acute aseptic arthritis, acute respiratory distress syndrome, Covidien-19 (disease increased after immunization) , anosmia and ageusia, and acute liver or kidney damage.
Pharmaceutical Management and Quality Service.
Directorate General for Health Management and Regulation.
medicaments.gencat.cat/ca/detalls/Article/2021016
(1) brightoncollaboration.us/priority-list-aesi-covid/
@Our Lady of Sorrows Healthcare professionals are asked not to report all adverse effects because there are too many, only the next ones should be reported: Priority List of Adverse Events of Special Interest: COVID-19